Skip to main content

Revvity company profile

  • RVTY · NYSE
  • Instruments
  • Health Care Equipment
  • S&P 500
$149.60+0.50%Close 17 Nov 2026 · Market value $16.67B

About Revvity

Revvity is a health science company headquartered in Waltham, Massachusetts, with approximately 11,000 employees as of December 28, 2025. It provides instruments, reagents, assay platforms, software and services for life sciences research and drug discovery, serving pharmaceutical, biotech, contract research, academic and government customers. Its Diagnostics business offers screening and testing products, including prenatal, newborn, genomic and immunodiagnostic tests, sold to hospitals, medical labs, clinicians and research professionals. The company markets its products and services in more than 160 countries, using its own sales forces in approximately 40 countries and distributors elsewhere.

A summary of the business section of the company's latest annual report, filed 24 Feb 2026.

Company facts

TickerRVTY · NYSE
SectorInstruments
IndustryHealth Care Equipment
IndexS&P 500
Fiscal year ends28 December
Reporting currencyUSD
CIK31791
Latest annual report10-K, filed 24 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Prahlad R. Singh, PhDPlease See Remarks · Director416K · < 1%Gift, 13 Aug 2026
Joel S. GoldbergPlease See Remarks169K · < 1%Gift, 14 Aug 2026
Alexis P. MichasDirector78.6K · < 1%Gift, 25 Aug 2026
Maxwell KrakowiakPlease See Remarks68.0K · < 1%Sale under a 10b5-1 plan, 21 Sep 2026
Miriame VictorPlease See Remarks54.0K · < 1%Option exercise, 24 Feb 2026
Tajinder S. VohraPlease See Remarks52.0K · < 1%Sale under a 10b5-1 plan, 16 Sep 2026
Peter BarrettDirector26.0K · < 1%Grant or award, 7 May 2026
Frank Witney, PhDDirector21.1K · < 1%Grant or award, 7 May 2026
Samuel R. ChapinDirector20.4K · < 1%Grant or award, 7 May 2026
Pascale WitzDirector13.7K · < 1%Grant or award, 7 May 2026
Michel VounatsosDirector11.7K · < 1%Grant or award, 7 May 2026
Michael A. KlobucharDirector5.1K · < 1%Grant or award, 7 May 2026
Sophie V. VandebroekDirector5.1K · < 1%Grant or award, 7 May 2026
Michelle McMurry-Heath, MD/PhDDirector4.8K · < 1%Grant or award, 7 May 2026
Gonzales AnitaVP and CAO—Sale under a 10b5-1 plan, 1 Oct 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

RVTY in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.